Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Real-world outcomes of standard and modified daratumumab-based therapy in AL amyloidosis: A cohort study from a multidisciplinary program in south India

View Full Paper
Ask AI
Bookmark
Share

Authors

NSNeeraj SidharthanGGGeorg GutjahrMEMrudula E.V.

Discussion

Loading...

Member takes

Overview

Cohort study shows improved hematologic responses with daratumumab in AL amyloidosis, suggesting treatment adaptations may be viable in LMICs.

Key Points

  • Modified-dose daratumumab retains significant efficacy, potentially reducing treatment costs.
  • In the cohort study, hematologic responses at 6 months were better with daratumumab compared to standard regimens.
  • Daratumumab therapy improved cardiac response rates, addressing complications from advanced AL Amyloidosis.
  • Findings support wider access to daratumumab-based treatments in resource-limited settings to improve patient outcomes.

Cite This Study

Sidharthan et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d802https://doi.org/10.1182/blood-2025-2820
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes of patients with mayo stage IIIb systemic AL amyloidosis treated with daratumumab-based frontline therapy2025
  2. 2Prognostic analysis of newly diagnosed systemic light-chain amyloidosis patients treated with daratumumab2025
  3. 3Real-world outcomes of daratumumab in light-chain amyloidosis patients with advanced renal failure: A TriNetX network study.2026
  4. 4Daratumumab-based regimens in newly diagnosed mayo 2004 stage 3b AL amyloidosis: A systematic review2025
  5. 5Daratumumab in AL amyloidosis: survival, cardiac CR, and beyond2026